Table 1. Trials characteristics summary.

Study	Recruitment	Number of patients	Stage	Total dose (Gy)	Fractions	Machine
Belgium (5)	1966–1977	202	I, II, III	60	30	Cobalto 60
LCSGS 773 (6)	1978–1985	230	II, III	50	25–27.5	Cobalto 60 + Linac
CAMS 12 (7)	1981–1995	317	II, III	60	30	Cobalto 60 + Linac
Lille 13 (8)	1985–1991	163	I	45–60	22.5–30	Cobalto 60 + Linac
EORTC 08861 (12)	1986–1990	106	II, III	56	28	Linac
MRC LU 11 (9)	1986–1993	308	II, III	40	15	Cobalto 60 + Linac
GETCB 04CB86 (11)	1986–1994	189	I, II, III	60	24–30	Cobalto 60 + Linac
Slovenia (10)	1988–1992	74	III	30	10–12	Cobalto 60 + Linac
GETCB 05CB88 (11)	1988–1994	539	I, II, III	60	24–30	Cobalto 60 + Linac
The Italy trial (12)	1989–1997	104	I	50.4	28	Linac
The Korea trial (13)	1989–1998	111	III	50.4–55.8	28–31	NR
Lung ART trial (3)	2007–2018	501	II, III	54	27	Linac